neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
Semaglutide launch in India on March 21, 2026
Dr. Reddy's will launch generic Ozempic (diabetes) in India on March 21, with all strengths including oral Rybelsus.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY26
Canada Semaglutide approval expected by May 2026
Health Canada response expected between end-February and May 2026, with launch preparation underway for Q4 or Q1.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY26
Global generics gross margin range 50%-55% post-lenalidomide
From Q4 FY26 onwards, without lenalidomide, global generics and PSAI gross margin expected in 50%-55% range.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1